2. Search Result
Search Result
Results for "

Kv 1.5

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14183
    Vernakalant Hydrochloride
    3 Publications Verification

    RSD1235 hydrochloride

    		 Potassium Channel Cardiovascular Disease
    Vernakalant hydrochloride is a mixed voltage- and frequency-dependent Na + and atria-preferred K + channel blocker. IC50 for block by Vernakalant of wild-type and mutant Kv1.5 channels Fractional block is 13.35±0.93 μM, 0.61±0.03 μM, and 1.63±0.09 μM for Kv1.5 channel wt, Kv1.5 channel I508F, Kv1.5 channel T479A, respectively.
    Vernakalant Hydrochloride
  • HY-107036
    BMS-394136

    		Potassium Channel Cardiovascular Disease
    BMS-394136 (compound 1) is a potent inhibitor of Kv 1.5, with an IC50 of 0.05 μM. BMS-394136 is a selective IKur inhibitor. BMS-394136 dose-dependently prolongs atrial effective refractory period (AERP) and action potential duration (APD) without effecting ventricular effective refractory period (VERP). BMS-394136 can be used for acute atrial ischemia research .
    BMS-394136
  • HY-118387
    AVE-0118

    		Potassium Channel Neurological Disease
    AVE-0118 is a nonselective Kv1.5 blocker with an IC50 of 1.1 μM. AVE-0118 is a multichannel inhibitor with weak, micromolar activity against Kv1.5 and other ion channels. It is inactive against IKs, IKATP, and L-type Ca+ channels .
    AVE-0118
  • HY-108574
    CP 339818 hydrochloride

    		Potassium Channel Neurological Disease
    CP 339818 hydrochloride is a nonpeptide and selective Kv1.3 (IC50 value of ~200 nM) and Kv1.4 channels blocker. CP 339818 hydrochloride is a significantly less potent blocker of Kv1.1, Kv1.2, Kv1.5, Kv1.6, Kv3.1-4, and Kv4.2. CP 339818 hydrochloride potently blocks the C-type inactivated conformation of Kv1.3 and suppresses T cell activation .
    CP 339818 hydrochloride
  • HY-144802
    DDO-02001

    		Potassium Channel Cardiovascular Disease
    DDO-02001 is a moderately potent Kv1.5 potassium channel inhibitor with an IC50 value of 17.7 μM. DDO-02001 can be used for researching anti-arrhythmia .
    DDO-02001
  • HY-100712
    DPO-1

    		Potassium Channel Cardiovascular Disease
    DPO-1 is a potent inhibitor of the voltage-gated potassium channel subtype Kv1.5 and a blocker of ultrarapid delayed rectifier potassium current. DPO-1 prevents atrial arrhythmia .
    DPO-1
  • HY-10015
    PAP-1
    Maximum Cited Publications
    8 Publications Verification

    5-(4-Phenoxybutoxy)psoralen

    		 Potassium Channel Inflammation/Immunology
    PAP-1 (5-(4-Phenoxybutoxy)psoralen) is a potent, selective, and orally active Kv1.3 blocker (EC50=2 nM). PAP-1 blocks Kv1.3 in a use-dependent manner and acts by preferentially binding to the C-type inactivated state of the channel. PAP-1 exhibits 23-fold selectivity over Kv1.5 (EC50=45 nM), and further displays 33- to 125-fold selectivity over all other Kv1-family channels. PAP-1 does not exhibit cytotoxic or phototoxic effects .
    PAP-1
  • HY-14186
    KVI-020

    WYE-160020

    		 Potassium Channel Cardiovascular Disease
    KVI-020 is an orally active, potent and selective blocker of the atrial potassium channel Kv1.5, with an IC50 of 480 nM. KVI-020 can inhibits hERG, with an IC50 of 15100 nM. KVI-020 is a potent antiarrhythmic agent, and can be used for atrial fibrillation (AF) research .
    KVI-020
  • HY-144801A
    DDO-02005

    		Potassium Channel Cardiovascular Disease
    DDO-02005 is a potent Kv1.5 potassium channel inhibitor with an IC50 value of 0.72 μM. DDO-02005 has good anti-atrial fibrillation (AF) effect in CaCl2-ACh AF rats model and effective anti-arrhythmic activity caused by aconitine .
    DDO-02005
  • HY-108587
    ICA 110381

    		Potassium Channel Neurological Disease
    ICA 110381 is an orally active Kv7.2/Kv7.3 (KCNQ2/3) potassium channel activator with anticonvulsive properties. ICA 110381 is a KCNQ2/Q3 activator (EC50=0.38 μM) as well as KCNQ1 antagonist (IC50=15 μM) .
    ICA 110381
  • HY-144801
    DDO-02005 free base

    		Potassium Channel Cardiovascular Disease
    DDO-02005 (free base) is a potent Kv1.5 potassium channel inhibitor with an IC50 value of 0.72 μM. DDO-02005 (free base) has good anti-atrial fibrillation (AF) effect in CaCl2-ACh AF rats model and effective anti-arrhythmic activity caused by aconitine .
    DDO-02005 free base
  • HY-B0189
    Mosapride

    TAK-370; AS-4370

    		 5-HT Receptor Cytochrome P450 Potassium Channel Neurological Disease Cancer
    Mosapride citrate is an orally active gastroenterokinetic compound. Mosapride citrate is a 5HT4agonist. Mosapride citrate is a CYP inducer. Mosapride citrate has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride citrate can be used in the study of gastrointestinal diseases .
    Mosapride
  • HY-B0189A
    Mosapride citrate
    3 Publications Verification

    TAK-370 citrate; AS-4370 citrate

    		 5-HT Receptor Potassium Channel Cytochrome P450 Neurological Disease Cancer
    Mosapride citrate is an orally active gastroenterokinetic compound. Mosapride citrate is a 5HT4 agonist. Mosapride citrate is a CYP inducer. Mosapride citrate has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride citrate can be used in the study of gastrointestinal diseases .
    Mosapride citrate
  • HY-B0189B
    Mosapride citrate dihydrate

    TAK-370 citrate dihydrate; AS-4370 citrate dihydrate

    		 5-HT Receptor Potassium Channel Cytochrome P450 Metabolic Disease
    Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM . Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo .
    Mosapride citrate dihydrate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: